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Background: The traditional Chinese theory of acupuncture emphasizes that the intensity of acupuncture must
reach a threshold to generate de qi (a specific and compound sensation during the acupuncture), which is
necessary to achieve the best therapeutic effect. However, the notion that de qi must be achieved for maximum
benefit has not been confirmed by modern scientific evidence. This study aims to compare the efficacy of
acupuncture with either strong (intended to elicit de qi) or weak stimulation among patients with allergic rhinitis.
Methods/Design: This study compares real versus sham acupuncture in 140 patients with a history of persistent
allergic rhinitis (PER) or intermittent allergic rhinitis (IAR) and with a positive skin prick test (SPT). The trial will be
conducted in the Teaching Hospital of Chengdu University of Traditional Chinese Medicine (China). In the study,
patients will be randomly assigned into two groups by computer-generated randomization and assessed prior to
treatment. They will then receive 12 sessions of treatments for 4 consecutive weeks and have a follow-up phase
lasting 12 weeks. The main outcome measures include the primary and secondary indicators. Primary indicators are
subjective symptoms scores as evaluated by visual analogue scales (VAS), rhinoconjunctivitis quality of life questionnaires
(RQLQ), and the Modified Massachusetts General Hospital acupuncture sensation scale, Chinese version (C-MMASS). The
secondary indicators are the results of laboratory examinations, such as serum allergen-specific immunoglobulin E (sIgE)
nasal inflammatory cells counts (mast cells, eosinophils, and T cells), and nitric oxide concentration in nasal excretion.
The use of anti-allergic medication will also be recorded as one of the secondary indicators. Furthermore, adverse events
will be recorded and analyzed. Intention-to-treat analysis (ITT) and per-protocol (PP) analysis will be performed to test
and verify the results in this trial.
Discussion: The results of this trial will demonstrate the efficacy of using acupuncture to treat allergic rhinitis and verify
whether the effectiveness of acupuncture is related to the needle sensation de qi.
Trial registration: Chinese Clinical Trial Registry: ChiCTR-TRC-13003594 (registered on 16 August 2013, and the first
patient was randomized on 27 September 2013).
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Allergic rhinitis (AR) is a symptomatic disorder of the
nose resulting from an immunoglobulin E (IgE) -mediated
immunological reaction to allergen exposure. Its major
symptoms include rhinorrhea, nasal itching, obstruction,
and sneezing, all of which are reversible either spontan-
eously or with treatment [1]. AR has become a major
health problem worldwide. It has been estimated by the
ARIA (Allergic Rhinitis and its Impact on Asthma) 2008
document that over 600 million patients from all coun-
tries, in all ethnic groups, and of all ages suffer from AR
[2]. It dramatically impacts quality of life (QOL) and cre-
ates a high economic burden. The conventional treatment
of AR symptoms, such as nasal obstruction, rhinorrhea,
sneezing, and itching, includes the use of intranasal corti-
costeroids, oral antihistamines with or without deconges-
tants, immunotherapy, and education [3]. A remarkable
number of patients with AR are not satisfied with conven-
tional medical treatment for they repeatedly experience
side effects and incur additional healthcare costs. As an
available and affordable treatment choice, acupuncture
has been accepted as a therapeutic option for relieving
symptoms of AR in China and other countries [4-6].
However, studies on the efficacy of acupuncture in pa-
tients with AR have yielded inconclusive results. For
example, Choi et al. [7] stated that active acupuncture
showed a significantly greater effect on symptoms of al-
lergic rhinitis than sham acupuncture, while Magnusson
et al. [8] found that there were no differences in clinical
symptoms which had been seen between active versus
sham acupuncture. At the same time, a number of trials
have the same situation in migraine [9,10], low back pain
[11,12] and some other diseases. All of those trials did
not find verum acupuncture more effective than sham
acupuncture and did not emphasize that the verum acu-
puncture group must have the needle sensation of de qi.
De qi is an internal compound sensation of soreness,
tingling, fullness, aching, coolness, warmth, heaviness,
and a radiating sensation at and around acupoints, and
is elicited by manipulation of the needles (rotated as well
as being moved both upward and downward). According
to the traditional theory and clinical practice, de qi is
one of the fundamental characteristics of acupuncture.
The importance of de qi was first mentioned circa 100
BC, in the Huangdi Neijing (The Yellow Emperor’s Clas-
sic of Internal Medicine). For example, Ling Shu (chap-
ter 1) [13] reads, ‘For acupuncture to be successful, the
qi must arrive (qi zhi). Acupuncture’s effects come about
like the clouds blown away by the wind.’ Another ex-
ample is in Ling Shu (chapter 9) where it is advised that
‘The acupuncturist should devote all his/her concentra-
tion to the needle, keep the needle on the surface and
move it gently, until the qi has arrived (qi zhi).’ There is
a long-held belief in the theory of acupuncture that theintensity of the stimulus must reach a certain threshold
to elicit de qi, which plays a pivotal role in achieving the
best therapeutic effects [14]. So far, more and more stud-
ies have begun to assess de qi by using different scales,
and to investigate the relationship between de qi and the
therapeutic effects [15,16]. However, this long-held belief
has not been confirmed by sufficient evidence from ran-
domized controlled trials about AR.
As mentioned above, we have designed a randomized,
double blind, large scale clinical trial to compare the effi-
cacy of acupuncture with either strong (intended to elicit
de qi) or weak stimulation among patients with AR. The
design and methodologies of this study have been ap-
proved by the Sichuan Regional Ethics Review Commit-
tee on Traditional Chinese Medicine with an ethics
approval number of 2013KL-025. The work reported in
this article is registered with the Chinese Clinical Trial
Registry (registration number: ChiCTR-TRC-13003594).
Methods/Design
Study design
This trial is a single center, double blind, sham group
randomized controlled trial, which will be performed at
the Department of Otorhinolaryngology, Head and Neck
Surgery, Teaching Hospital of Chengdu University of
Traditional Chinese Medicine, China. The study will be
sequentially conducted as follows: a run-in period of 2
weeks prior to randomization, a treatment period of 4
weeks (3 sessions per week), and a follow-up period of
12 weeks. The total study period will be 18 weeks. At
the end of the run-in period participants will be ran-
domized to the active acupuncture group or the sham
acupuncture group by a computer-generated random
number list (Figure 1).
Randomization and blinding
The randomization sequence will be computer generated
by independent research staff using software called
Statistical Program for Social Sciences (SPSS 18.0 IBM
China Company headquarters, Beijing, China). After
randomization, group assignments will be concealed in
light-proof and sealed sequentially numbered envelopes.
The included participants will be randomly enrolled by
sealed envelope and assigned to the de qi group or
sham-acupuncture control group in a ratio of 1:1. Then
the person in charge of the envelopes will give the speci-
fied envelope to the acupuncturist. To preserve masking,
only the acupuncturists will have access to the treatment
allocation.
Randomization will be performed by researchers who
are not in direct contact with the participants. Partici-
pants, researchers, and study physicians who interview
and recruit patients are blinded to the group assign-
ments. The acupuncture practitioners will be informed
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Figure 1 Screening, recruitment, randomization, and participant
follow-up schedule of the trial. C-MMASS, Modified Chinese version
of the Massachusetts General Hospital Acupuncture Sensation Scale;
RQLQ, Rhinoconjunctivitis Quality of Life Questionnaires; VAS, Visual
analog scales.
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asked not to communicate with the participants or as-
sessors regarding treatment procedures and responses.
The two randomized groups will be named A or B in
the medical records and the case report forms will not
be directly linked to the treatment. All information will
be locked out and saved in a database before statistical
analysis is performed. After statistical analysis, the blind
exposure will be provided.
Inclusion criteria
Each participant must have a diagnosis of AR by an Oto-
laryngology doctor, according to the criteria listed in ‘Al-
lergic Rhinitis and its Impact on Asthma’ (ARIA 2008
[2]) Patients who will be recruited in this study should
meet the following inclusion criteria: (1) Male or female
aged between 18 and 65 years. (2) Presenting with typ-
ical symptoms of AR, such as rhinorrhea, sneezing, nasal
obstruction, and pruritus. These symptoms should last
for more than one hour on most days. Some patients
may have ocular symptoms due to outdoor allergens. (3)
Having at least one positive result among the followinglaboratory findings: elevated total blood IgE level or
positive skin prick test reaction. (4) Providing an in-
formed written approval. (5) No current participation in
any other clinical trials.
Exclusion criteria
Patients with any of the following conditions will be ex-
cluded: (1) Patients are receiving immune therapy. (2)
Patients have received systemically administered cortico-
steroids, antihistamines, or decongestants within the
most recent six months. (3) Patients with other allergic
diseases, such as bronchial asthma or allergic purpura.
(4) Patients with nasal polyposis and congenital nasal ab-
normalities including nasal dermoid cysts and congenital
midline nasal masses, sinusitis, or asthma. (5) Patients
with serious medical conditions, such as liver or kidney
dysfunction, severe dyslipidemia, AIDS, vascular malfor-
mation, hypertension, hematologic diseases, diabetes
mellitus, a past or current malignant tumor, mental dis-
orders and other infectious or systemic diseases that
would make treatment with acupuncture inappropriate.
(6) Pregnant women or women who have been trying to
get pregnant in the last six months, or women who are
lactating.
Withdrawal from the study
All participation in the trial is voluntary. Participants
have the right to withdraw from the study at any time
for any reason without any consequences for further
medical treatment. Also, investigators have the right to
terminate the participation of any patients if any severe
adverse events occur or any events that may hurt the
participant’s interest. The reasons and circumstances for
study discontinuation will be documented in the case re-
port form. All data are analyzed based on the intention-
to-treat (ITT) principle.
Recruitment
Patients will be recruited at the otorhinolaryngology
clinic at the Affiliated Hospital of Chengdu University of
Traditional Chinese Medicine. At the same time, televi-
sion advertisements will be broadcast on local channels
to promote study participation. Advertisements will also
be published in local newspapers. Printed recruitment
posters will be posted in the hospital.
Interventions
During the treatment process, all participants will be ex-
plained the meaning of acupuncture and de qi by the
acupuncturists in the same way. Both the de qi and con-
trol group participants will receive acupuncture treat-
ments respectively, 3 times a week for a total of 12
sessions over 4 weeks. The same number and type of
needles (Hwato disposable sterile acupuncture needles
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be used for both groups. The needle selected was 0.30
mm in diameter and the length of the needle selected
varied according to the point location. Needle sites in both
active and sham acupuncture groups will be swabbed with
75% alcohol before insertion. On withdrawal of the needle,
dry sterilized cotton balls will be firmly applied to the in-
sertion points. Medications which could affect the allergic
rhinitis symptoms are not permitted.
In the de qi group, the needle was inserted trans-
versely, obliquely, or perpendicularly depending on the
acupoints selected with 10 to 30 mm in depth. The acu-
puncturist will manipulate the needles manually after in-
sertion, using techniques such as lifting, thrusting, and
twirling, until de qi was achieved. The needles will be
left in place for 30 minutes. During the treatment ses-
sion, the patient will be asked about de qi every 10 mi-
nutes and the needles will be manipulated to maintain
the intensity of the sensation (Table 1). In the control
group the needles will be inserted to a depth of 3 to 5 mm
perpendicularly to the skin and left in place for 30 minutes
without manipulation. Patients in the other treatment
group are treated in different rooms. All sessions for each
patient were performed by the same acupuncturist.
The acupuncture intervention was based on traditional
Chinese acupuncture theory and previous Chinese lit-
erature. These acupoints (bilateral: Yingxiang-LI20, Hegu-
LI4, Quchi-LI11, Zusanli-ST36, unilateral: Yintang -EX-HN3)
are selected according to the ‘WHO Standard Acupunc-
ture Point Location’ [17]. According to traditional acu-
puncture theories, we know that the key pathogenesis of
AR is an invasion of pathogenic agents such as cold, wind,
and damp, which lead to the imbalance of the large intes-
tine, stomach meridian, or governor vessel. Thus, the
most frequently used specific acupoints for these merid-
ians would be selected in this trial according to a previous
review of ancient and modern literature. Yingxiang (LI20)
is considered as a specific point on Yangming’s largeTable 1 Needling procedure for de qi group
Real point Angle and Direction Depth
(mm)
LI20 (both) Obliquely along the nasolabial sulcus




LI4 (both) Perpendicular to the skin 20-30
Hegu
LI11 (both) Perpendicular to the skin 20-30
Quchi
ST36 (both) Perpendicular to the skin, between the
tibia and the fibula
20-30
Zusanli
EX-NH3 (unilateral) Transversely, downward towards the
root of the nose
10-20
Yingtangintestine meridian of hand. Hegu (LI4) is the source point
of the large intestine meridian. Therefore, LI20, ST36, and
EX-NH3 are selected to disperse pathologic Qi and blood
from these meridians and improve the function of the
nose and sinuses. The ancient Chinese believed that
Yangming is a meridian abundant with blood and Qi and
is the acquired foundation. Zusanli and Quchi will be used
to fortify the spleen and replenish lung Qi.
Ethics
This trial is performed according to the principles of the
Declaration of Helsinki (Edinburgh 2000). The trial proto-
col has been approved by the Sichuan Regional Ethics Re-
view Committee on Traditional Chinese Medicine. Written
informed consent will be obtained from each participant
before registration. All patients will be given enough time
to decide whether they would sign the informed consent,
or they will be given treatment options other than acu-
puncture if they are not willing to participate.
Outcome measurements
Primary outcomes
For the evaluation of the main outcome measures pa-
tients are requested to fill in a questionnaire including
the Rhinitis Quality of Life Questionnaire (RQLQ) [18,19],
the visual analogue scale (VAS) [20] and C-MMASS
(Massachusetts General Hospital Acupuncture Sensation
Scale, modified Chinese version) [21].
In VAS, the severity of the combination of the nasal
symptoms will be subjectively rated by the study patients
on the scale. The severity of symptoms can be divided
into mild, moderate, or severe based on the total severity
VAS score (0 to 10 cm: mild, VAS 0 to 3; moderate, VAS
3.1 to 7; severe, VAS 7.1 to 10). VAS scores will be re-
corded every two weeks throughout the whole trial.
The RQLQ (see Additional file 1) evaluates impair-
ment of everyday life (activity, sleep, everyday life prob-
lems, condition of health) caused by symptoms of the
eyes and nose. It contains 28 questions related to these
dimensions. Each question can be divided into seven de-
grees: 0 - not trouble, 1 - any trouble at all, 2 - somewhat
troubled, 3 - moderately troubled, 4 - quite a bit of
trouble, 5 - very troubled, 6 - extremely troubled. It will
be measured by questionnaire at baseline, at the end of
treatment, during the follow-up period, and at the end of
the follow-up period (a total of five times). Both the scores
of VAS and RQLQ questionnaire will be blindly assessed.
C-MMASS (see Additional file 2) is an accepted method
of objectively scoring the sensation of de qi. Immediately
after removing the needles during the 1st, 3rd, 5th, 7th,
9th, and 12th sessions, patients will be asked to fill in the
questionnaire. Patients were questioned about whether
each of the sensations of de qi had occurred during the
session.
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Secondary outcome measures include serum allergen-
specific IgE, blood eosinophil count, nasal inflammatory
cells counts (mast cells, eosinophils, and T cells), the
level of nitric oxide concentration in nasal secretion, and
side effects. The patients were examined by the otolaryn-
gologist at the following times: on entering the study, at
the end of the run-in period, in the middle and at the
end of the treatment phase, and every 4 weeks during
the follow-up phase. Nasal secretions and blood samples
will be collected on entry, at the end of the treatment
phase, and at 4 and 8 weeks after the end of treatment.
Adverse events of acupuncture, if any, will be checked
and recorded (Table 2).
To test the effectiveness of blinding, patients in the acu-
puncture and sham acupuncture groups fill in a question-
naire after the third acupuncture session to assess the
credibility of the respective treatment methods [22].
Sample size calculation
Considering participants recruited in the two groups are
in a 1:1 ratio, the following formula was used to estimate
sample size [23]:












In the formula: n1, n2 represent the sample size of
each group. π1, π2 is the overall rate of each sample, re-
spectively. πc = (π1 + π2)/2, α = 0.05, Z0.05 = 1.96, β = 0.10,
Z0.10 = 1.282. According to the previous literature [24],Table 2 Outcome measurements











Skin prick tests √
Randomization √
VAS √ √ √ √ √ √ √ √ √
RQLQ √ √ √ √ √
C-MMASS √ √ √ √
Laboratory √ √ √ √
Adverse event √ √ √ √ √ √ √ √ √ √ √
C-MMASS, Modified Chinese version of the Massachusetts General Hospital
Acupuncture Sensation Scale; RQLQ, Rhinoconjunctivitis Quality of Life
Questionnaires; VAS, Visual analog scales. The numbers at top of figure are
weeks. On the left of the figure, it shows weeks.statistical analysis will be performed using a 5% signifi-
cance and 90% power, resulting in an estimated 70 pa-
tients per group with the dropout rate of 20%.
Statistical analysis
Analysis of all data in this trial will be performed by the
National Clinical Trial Center of Chinese Medicine
(Chengdu GCP Center) in China, which is performed in
a blinded manner because analysis of data is done by a
special analysis-researcher. The data will be analyzed
with SPSS 18.0 and SAS 9.0 (SAS Institute Inc. 100 SAS
Campus Drive Cary, NC 27513-2414, USA) statistical
software packages. Results will be summarized as means,
standard deviations, and 95% confidence intervals (CIs)
for continuous data, medians, quartiles, and ranges for
rank data, and frequencies and percentages for discrete
data.
The first step of analysis is to check whether de qi
groups were more efficacious in treating AR than the
control group. If de qi treatment is more effective than
the control group in treating AR, the next step is to
make comparisons among de qi group in the relation-
ship between the effectiveness of treating AR and the
scores of the C-MMASS.
The intention-to-treat (ITT) group is defined as the
patients who are randomized. The per-protocol (PP)
group is defined as the patients who completed the
study and do not have major protocol violations. All
analyses were based on the ITT group and PP group.
And the result of the ITT analysis will be compared with
that of the PP analysis to check whether the results are
consistent.
Discussion
The main objective of this trial is to investigate the rela-
tionship between the effect of the acupuncture for pa-
tients with AR and the needle sensation of de qi. This
objective has two aspects: one is whether acupuncture
with de qi is more efficient than without de qi; the other
is the relationship between de qi and efficiency. In this
trial, we assess the strength of de qi by the score of C-
MMASS and the efficiency by the score of RQLQ. We
want to know whether a high score equates to high effi-
ciency or not. The result of this trial is expected to pro-
vide convincing evidence that strengthened stimulation
during acupuncture for the treatment of allergic rhinitis
is more effective.
In the literature, sham acupuncture is considered to be
a placebo treatment in acupuncture studies. There are
two common types of sham control for the clinical study
for acupuncture, one is a technique in which needles are
inserted shallowly at defined acupoints, another is at lo-
cations of 1 to 2 cm away from the defined acupoints. In
our study we chose to use the point superficial needle-
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points to a depth of 3 mm and are retained at the subcuta-
neous level. To ensure the efficacy and safety of the treat-
ment, acupuncturists should undergo special training in
Teaching Hospital of Chengdu University of Traditional
Chinese Medicine and have sufficient knowledge, special
technique, and good experience in acupuncture.Trial status
This trial is currently recruiting participants (began at 1
September 2013).Additional files
Additional file 1: Chinese vision of RQLQ. Questionnaire to measure
the quality of Life.
Additional file 2: C-MMASS. Questionnaire to objectively scoring the
sensation of de qi.
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